927 related articles for article (PubMed ID: 9336349)
1. Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716.
Major TC; Keiser JA
J Pharmacol Exp Ther; 1997 Oct; 283(1):402-10. PubMed ID: 9336349
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor.
Dahring TK; Lu GH; Hamby JM; Batley BL; Kraker AJ; Panek RL
J Pharmacol Exp Ther; 1997 Jun; 281(3):1446-56. PubMed ID: 9190882
[TBL] [Abstract][Full Text] [Related]
3. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
Panek RL; Lu GH; Klutchko SR; Batley BL; Dahring TK; Hamby JM; Hallak H; Doherty AM; Keiser JA
J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of inhibition by heparin of PDGF stimulated MAP kinase activation in vascular smooth muscle cells.
Pukac LA; Carter JE; Ottlinger ME; Karnovsky MJ
J Cell Physiol; 1997 Jul; 172(1):69-78. PubMed ID: 9207927
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Druker BJ; Lydon NB
Cancer Res; 1996 Jan; 56(1):100-4. PubMed ID: 8548747
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of basic fibroblast growth factor-mediated tyrosine phosphorylation and protein synthesis by PD 145709, a member of the 2-thioindole class of tyrosine kinase inhibitors.
Fry DW; Nelson JM
Anticancer Drug Des; 1995 Dec; 10(8):607-22. PubMed ID: 8595121
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.
Shawver LK; Schwartz DP; Mann E; Chen H; Tsai J; Chu L; Taylorson L; Longhi M; Meredith S; Germain L; Jacobs JS; Tang C; Ullrich A; Berens ME; Hersh E; McMahon G; Hirth KP; Powell TJ
Clin Cancer Res; 1997 Jul; 3(7):1167-77. PubMed ID: 9815796
[TBL] [Abstract][Full Text] [Related]
8. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.
Panek RL; Lu GH; Dahring TK; Batley BL; Connolly C; Hamby JM; Brown KJ
J Pharmacol Exp Ther; 1998 Jul; 286(1):569-77. PubMed ID: 9655904
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation.
Lipson KE; Pang L; Huber LJ; Chen H; Tsai JM; Hirth P; Gazit A; Levitzki A; McMahon G
J Pharmacol Exp Ther; 1998 May; 285(2):844-52. PubMed ID: 9580635
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
11. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation.
Kovalenko M; Gazit A; Böhmer A; Rorsman C; Rönnstrand L; Heldin CH; Waltenberger J; Böhmer FD; Levitzki A
Cancer Res; 1994 Dec; 54(23):6106-14. PubMed ID: 7954456
[TBL] [Abstract][Full Text] [Related]
12. Signal transduction by basic fibroblast growth factor in rat osteoblastic Py1a cells.
Hurley MM; Marcello K; Abreu C; Kessler M
J Bone Miner Res; 1996 Sep; 11(9):1256-63. PubMed ID: 8864900
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor.
Reddy KB; Mangold GL; Tandon AK; Yoneda T; Mundy GR; Zilberstein A; Osborne CK
Cancer Res; 1992 Jul; 52(13):3636-41. PubMed ID: 1617636
[TBL] [Abstract][Full Text] [Related]
14. Interrelationships of platelet-derived growth factor isoform-induced changes in c-fos expression, intracellular free calcium, and mitogenesis.
Diliberto PA; Bernacki SH; Herman B
J Cell Biochem; 1990 Sep; 44(1):39-53. PubMed ID: 2135398
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of lovastatin on mitogen induced calcium influx in human cultured vascular smooth muscle cells.
Clunn GF; Lymn JS; Schachter M; Hughes AD
Br J Pharmacol; 1997 Aug; 121(8):1789-95. PubMed ID: 9283719
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Regenass U; Lydon NB
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2558-62. PubMed ID: 7708684
[TBL] [Abstract][Full Text] [Related]
17. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative action of cudraflavone B, isolated from Cudrania tricuspidata, through the downregulation of pRb phosphorylation in aortic smooth muscle cell proliferation signaling.
Kim TJ; Han HJ; Lim Y; Song MC; Kim J; Hong JT; Yoo HS; Pyo MY; Hwang BY; Lee MK; Yun YP
J Cardiovasc Pharmacol; 2009 Apr; 53(4):341-8. PubMed ID: 19295442
[TBL] [Abstract][Full Text] [Related]
19. Pregnancy-stimulated growth of vascular smooth muscle cells: importance of protein kinase C-dependent synergy between estrogen and platelet-derived growth factor.
Keyes LE; Moore LG; Walchak SJ; Dempsey EC
J Cell Physiol; 1996 Jan; 166(1):22-32. PubMed ID: 8557771
[TBL] [Abstract][Full Text] [Related]
20. Protamine inhibits platelet derived growth factor receptor activity but not epidermal growth factor activity.
Huang JS; Nishimura J; Huang SS; Deuel TF
J Cell Biochem; 1984; 26(4):205-20. PubMed ID: 6099364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
